Get the Stockscreener App
2.05
2.57%
0.07
Pacific Biosciences Of California Inc stock is traded at $2.05, with a volume of 447.97K.
It is up +2.57% in the last 24 hours and down -15.03% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.98
Open:
$2.01
24h Volume:
447.97K
Relative Volume:
0.05
Market Cap:
$617.40M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.3667
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+17.39%
1M Performance:
-15.03%
6M Performance:
+26.93%
1Y Performance:
+2.05%
1-Day Range:
$2.00
$2.05
1-Week Range:
$1.75
$2.035
52-Week Range:
$0.8511
$2.725
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.045 | 597.78M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
128.32 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.31 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.39 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.47 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.58 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Three Genomics Stocks Worth Tracking This Year - Nasdaq
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt - simplywall.st
What drives Pacific Biosciences of California Inc P09 stock priceMarket Volatility Update & Missed Nvidia? Don’t Miss This One - earlytimes.in
Retail Surge: Will Pacific Biosciences of California Inc P09 stock rise with strong economyJuly 2025 Volume & Low Risk Entry Point Tips - moha.gov.vn
Stocks making big moves this week: PacBio, Crocs, FuelCell Energy, AMC Entertainment, and ON24 - The Globe and Mail
PacBio (PACB) Stock Is Up, What You Need To Know - Finviz
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpTime to Buy? - MarketBeat
What analysts say about Pacific Biosciences of California Inc P09 stockTechnical Resistance Breaks & Outstanding Capital Returns - earlytimes.in
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio - The Globe and Mail
Why Is PacBio (PACB) Stock Soaring Today - Finviz
Cathie Wood’s Strategic Move: ARK Investment Buys PacBio Shares - StocksToTrade
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 7.1%Should You Buy? - MarketBeat
Cathie Wood’s ARK Investment Fuels PacBio Stock Surge - timothysykes.com
Barclays Analyst Is Bullish On Pacific Biosciences of California, Inc. (PACB) - Finviz
PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
12 Best Genomics Stocks to Invest In - Insider Monkey
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 5.1%What's Next? - MarketBeat
ARK Investment Acquires Additional Shares of PacBio (PACB) - GuruFocus
Cathie Wood’s ARK buys Weride, Pacific Biosciences stocks, sells Ibotta By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Weride, Pacific Biosciences stocks, sells Ibotta - Investing.com
What analysts say about Pacific Biosciences of California Inc stockStock Buyback Announcements & Free Stay Ahead With Picks - earlytimes.in
ARK Investment Acquires Significant Stake in PacBio (PACB) - GuruFocus
Pacific Biosciences unveils gift campaign with coffee subscription giveaway - Traders Union
Pacific Biosciences of California Target of Unusually Large Options Trading (NASDAQ:PACB) - MarketBeat
Will Pacific Biosciences of California Inc. stock maintain dividend yieldJuly 2025 Decliners & Fast Moving Stock Watchlists - Улправда
Is Pacific Biosciences of California Inc. (P09) stock ideal for retirement investorsMarket Growth Review & Technical Entry and Exit Tips - ulpravda.ru
How Pacific Biosciences of California Inc. stock valuations compare to rivalsInsider Selling & Long-Term Investment Growth Plans - Улправда
Pacific Biosciences of California (HAM:P09) EV-to-OCF : -7.32 (As of Dec. 20, 2025) - GuruFocus
What insider trading reveals about Pacific Biosciences of California Inc. stockQuarterly Portfolio Review & Weekly High Return Forecasts - Улправда
Aug Mood: What insider trading reveals about Pacific Biosciences of California Inc. stock - Улправда
What technical charts say about Pacific Biosciences of California Inc. stock2025 Trading Volume Trends & Real-Time Sentiment Analysis - DonanımHaber
How Pacific Biosciences of California Inc. stock reacts to Fed rate cutsPortfolio Growth Summary & Free Safe Entry Trade Signal Reports - DonanımHaber
Can Pacific Biosciences of California Inc. stock double in next 5 years2025 Macro Impact & AI Based Buy/Sell Signal Reports - Улправда
Is Pacific Biosciences of California Inc. stock a defensive play in 2025GDP Growth & Weekly High Momentum Picks - Улправда
Highs Report: Is Pacific Biosciences of California Inc. stock a defensive play in 2025 - ulpravda.ru
Quarterly Risk: Will Pacific Biosciences of California Inc. stock maintain dividend yield2025 Growth vs Value & High Win Rate Trade Tips - Улправда
US Market Wrap: Will Pacific Biosciences of California Inc. stock pay special dividendsPortfolio Risk Report & Pattern Based Trade Signal System - Улправда
Is Pacific Biosciences of California Inc. stock safe for conservative investorsWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - Улправда
Pacific Biosciences: Longer Reads, But Shorter Patience (Downgrade) (PACB) - Seeking Alpha
What technical signals suggest for Pacific Biosciences of California Inc. stockOptions Play & AI Forecasted Stock Moves - Улправда
How risky is Pacific Biosciences of California Inc. stock now2025 Fundamental Recap & Weekly Market Pulse Updates - Улправда
MACD Signal: Can Pacific Biosciences of California Inc. stock double in next 5 yearsWeekly Trade Recap & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Barclays Maintains Pacific Biosciences of California (PACB) Equal-Weight Recommendation - Nasdaq
Barclays Maintains Rating and Increases Price Target for PACB | - GuruFocus
Barclays Issues Positive Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price - MarketBeat
Amiral Gestion Invests $3.21 Million in Pacific Biosciences of California, Inc. $PACB - MarketBeat
Market Participants Recognise Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Revenues Pushing Shares 32% Higher - 富途牛牛
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):